Home
COSM
COSM News

Latest Cosmos Health Inc. (COSM) News on October 6, 2025

Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units

GlobeNewswire

3 days ago

Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units

Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units

GlobeNewswire

25 days ago

Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units

Cosmos Health enters U.S. market with DolCas Biotech agreement

TipRanks

3 months ago

Cosmos Health enters U.S. market with DolCas Biotech agreement

MT Newswires

3 months ago

Cosmos Health to Begin Production in US to Mitigate Tariff Exposure

Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech

GlobeNewswire

3 months ago

Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

GlobeNewswire

5 months ago

RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

GlobeNewswire

5 months ago

Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven

Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

GlobeNewswire

5 months ago

Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq

GlobeNewswire

5 months ago

Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

GlobeNewswire

5 months ago

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Argus Research

5 months ago

Daily – Vickers Top Buyers & Sellers for 04/29/2025

Argus Research

5 months ago

Daily – Vickers Top Buyers & Sellers for 04/24/2025

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

GlobeNewswire

6 months ago

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L

GlobeNewswire

6 months ago

Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L

Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order

GlobeNewswire

6 months ago

Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/20/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/19/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/18/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/17/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/14/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/13/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/12/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/11/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/10/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/07/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/06/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/05/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/04/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 03/03/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 02/28/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 02/27/2025

ACCESS Newswire

7 months ago

Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 02/26/2025

Argus Research

7 months ago

Daily – Vickers Top Buyers & Sellers for 02/26/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 02/25/2025

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 02/24/2025

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/21/2025

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/20/2025

Bullish Cosmos Health Insiders Loaded Up On US$539.0k Of Stock

Simply Wall St.

8 months ago

Bullish Cosmos Health Insiders Loaded Up On US$539.0k Of Stock

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/19/2025

Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1

ACCESS Newswire

8 months ago

Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/18/2025

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/14/2025

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/13/2025

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/12/2025

Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market

ACCESS Newswire

8 months ago

Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/11/2025

Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market

ACCESS Newswire

8 months ago

Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market

Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations

ACCESS Newswire

8 months ago

Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/10/2025

Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility

ACCESS Newswire

8 months ago

Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/07/2025

Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar

ACCESS Newswire

8 months ago

Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/06/2025

Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market

ACCESS Newswire

8 months ago

Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/05/2025

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/04/2025

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/03/2025

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 01/31/2025

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 01/30/2025

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 01/29/2025

Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow

ACCESS Newswire

8 months ago

Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 01/28/2025

Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion

ACCESS Newswire

8 months ago

Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 01/27/2025

Argus Research

8 months ago

Daily – Vickers Top Buyers & Sellers for 01/24/2025

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 01/24/2025

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

ACCESS Newswire

8 months ago

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 01/23/2025

Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million

ACCESS Newswire

8 months ago

Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million

Argus Research

8 months ago

Daily – Vickers Top Buyers & Sellers for 01/22/2025

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 01/22/2025

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

ACCESS Newswire

8 months ago

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Argus Research

9 months ago

Daily – Vickers Top Buyers & Sellers for 01/21/2025

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 01/21/2025

Argus Research

9 months ago

Daily – Vickers Top Buyers & Sellers for 01/17/2025

Argus Research

9 months ago

Daily – Vickers Top Buyers & Sellers for 01/16/2025

Argus Research

9 months ago

Daily – Vickers Top Buyers & Sellers for 01/15/2025

Cosmos Health secures exclusive distribution agreement with Virax Biolabs

TipRanks

9 months ago

Cosmos Health secures exclusive distribution agreement with Virax Biolabs

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

ACCESS Newswire

9 months ago

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

ACCESSWIRE

9 months ago

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000

ACCESSWIRE

9 months ago

Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000

Taglich Brothers Releases Updated Coverage on Cosmos Health: Projects Positive EPS for 2025 and Sets $3 Price Target, Nearly 300% Above Current Share Price

ACCESSWIRE

10 months ago

Taglich Brothers Releases Updated Coverage on Cosmos Health: Projects Positive EPS for 2025 and Sets $3 Price Target, Nearly 300% Above Current Share Price

Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets

ACCESSWIRE

a year ago

Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets

Cosmos Health Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

a year ago

Cosmos Health Third Quarter 2024 Earnings: Misses Expectations

Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M

ACCESSWIRE

a year ago

Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M

Cosmos Health Issues Letter to Shareholders

ACCESSWIRE

a year ago

Cosmos Health Issues Letter to Shareholders

Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%

ACCESSWIRE

a year ago

Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%

ACCESSWIRE

a year ago

Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands

ACCESSWIRE

a year ago

Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins

ACCESSWIRE

a year ago

Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits

Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion

ACCESSWIRE

a year ago

Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion

Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments

ACCESSWIRE

a year ago

Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments

Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price

ACCESSWIRE

a year ago

Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price

Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar

ACCESSWIRE

a year ago

Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

PR Newswire

a year ago

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements

ACCESSWIRE

a year ago

Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements

Cosmos Health Holds EU Distribution Rights for Virax Biolabs’ Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits

ACCESSWIRE

a year ago

Cosmos Health Holds EU Distribution Rights for Virax Biolabs’ Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits

Cosmos Health Reports Q2 2024 Results: Sustains Positive Momentum with 7% Revenue Growth vs. Q1 2023 and 12.5% vs. H1 2023

ACCESSWIRE

a year ago

Cosmos Health Reports Q2 2024 Results: Sustains Positive Momentum with 7% Revenue Growth vs. Q1 2023 and 12.5% vs. H1 2023

Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross Profit

ACCESSWIRE

a year ago

Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross Profit

Share on Social Networks: